For 36 years, Bilal Egilmez, who learned his trade in Turkey, has altered and mended clothing at Genius Tailor, his Upper East Side shop.
NYS Entity Status
- Dissolution (May 15, 2014)
NYS Filing Date
NOVEMBER 26, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - LENOX RX DRUGS INC
Around the Web
- Neighborhood Joint: Tailoring in a Basement? It Suits Him
By SYLVIE BIGAR - Wednesday Jun 28, 2017
- 1 in 3 Americans Took Rx Opioid Painkillers, Survey Says
By Corky Siemaszko - Monday Jul 31, 2017
The stunning number comes from a new survey released Monday from the National Institute on Drug Abuse, which calculated that a whopping 91.8 million Americans used drugs like OxyContin or Vicodin in 2015.
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.
- Most hated man in US soccer accused of ties to drug kingpin
By Brian Lewis, Kaja Whitehouse - Wednesday Aug 9, 2017
Rafael “Rafa” Marquez – who played for the NY Red Bulls before becoming captain of Mexico’s National Team – has been secretly acting as a frontman for a Mexican drug kingpin, according to the US Treasury Dept. Marquez, 37, is one of close to two dozen people the Treasury Dept. on Wednesday said has been helping hide...
- Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
By Ben Fidler - Monday Sep 11, 2017
A new drug for patients who have a hard time controlling their asthma could be nearing an FDA review. Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and partner Sanofi this morning are touting results this morning from a 1,902-patient Phase 3 study called Liberty Asthma Quest. In it, their injectable antibody drug dupilumab (Dupixent), already approved […]